VU0453379 is a highly selective CNS penetrant positive allosteric modulator of Glucagon-like peptide-1 (GLP-1) with GLP-1 EC50 = 1.3 µ,M, 59.2% GLP-1 max. VU0453379 potentiated low-dose exenatide to augment insulin secretion in primary mouse pancreatic islets. In a model of Parkinson’;s disease it showed a significant reversal of haloperidol-induced catalepsy at 30 mg/kg.